Last reviewed · How we verify

Veklury — Competitive Intelligence Brief

Veklury (Veklury) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside analog prodrug. Area: Metabolic.

marketed Nucleoside analog prodrug NS5, Replicase polyprotein 1ab Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Veklury (Veklury) — ANRS, Emerging Infectious Diseases.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Veklury TARGET Veklury ANRS, Emerging Infectious Diseases marketed Nucleoside analog prodrug NS5, Replicase polyprotein 1ab

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside analog prodrug class)

  1. ANRS, Emerging Infectious Diseases · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Veklury — Competitive Intelligence Brief. https://druglandscape.com/ci/veklury. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: